Drug intelligence / Profile preview

tetraethylammonium + quinine + tolbutamide

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of three small molecule drugs: - **Tetraethylammonium** is a quaternary ammonium compound primarily used as an experimental pharmacological agent. It acts as a non-selective blocker of various potassium channels, blocks autonomic ganglia, and inhibits nicotinic acetylcholine receptors. Historically, it was investigated for use as a vasodilator and in neurological conditions but is not approved for any indication due to toxicity concerns[1][2][4]. - **Quinine** is an alkaloid with antimalarial properties that also has activity as a sodium channel blocker and can affect cardiac conduction. - **Tolbutamide** is an oral first-generation sulfonylurea antidiabetic agent used to lower blood glucose in type 2 diabetes mellitus by stimulating insulin release from pancreatic β-cells[7][10]. No evidence was found that this specific triple combination (tetraethylammonium + quinine + tolbutamide) has been developed or marketed under any brand or code name. Each component has distinct mechanisms of action.

02

Targets

KATP channel (ATP-sensitive potassium channel)KCNN1 (Small conductance calcium-activated potassium channel protein 1)HCN (HCN channel family)Nicotinic Acetylcholine ReceptorSUR1 (Sulfonylurea receptor 1)Kir (Inward-rectifier potassium channels)KCNMB4 (Potassium calcium-activated channel subfamily M regulatory beta subunit 4)KCNA5 (Ultra-rapid delayed rectifier potassium channel)SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on tetraethylammonium + quinine + tolbutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetraethylammonium + quinine + tolbutamide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call